See more : China Literature Limited (CHLLF) Income Statement Analysis – Financial Results
Complete financial analysis of Surrozen, Inc. (SRZNW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Surrozen, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Choushimaru Co.,Ltd. (3075.T) Income Statement Analysis – Financial Results
- MEDIPOST Co., Ltd. (078160.KQ) Income Statement Analysis – Financial Results
- Itafos Inc. (MBCF) Income Statement Analysis – Financial Results
- PT Bank Mayapada Internasional Tbk (MAYA.JK) Income Statement Analysis – Financial Results
- Northern Genesis Acquisition Corp. III (NGC-UN) Income Statement Analysis – Financial Results
Surrozen, Inc. (SRZNW)
About Surrozen, Inc.
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies to engage the body's existing biological repair mechanisms with potential application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 that stimulates hepatocyte regeneration, improves liver function, and reduces fibrosis; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are highly expressed in intestinal crypts. The company was founded in 2016 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 12.50M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 27.23M | 3.27M | 3.30M | 2.93M | 0.00 |
| Gross Profit | -27.23M | 9.23M | -3.30M | -2.93M | 0.00 |
| Gross Profit Ratio | 0.00% | 73.85% | 0.00% | 0.00% | 0.00% |
| Research & Development | 27.23M | 37.01M | 40.18M | 25.68M | 19.60M |
| General & Administrative | 15.80M | 19.83M | 14.21M | 7.12M | 5.50M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.80M | 19.83M | 14.21M | 7.12M | 5.50M |
| Other Expenses | -24.48M | 7.55M | -329.00K | 0.00 | 0.00 |
| Operating Expenses | 18.55M | 56.84M | 54.39M | 32.81M | 24.81M |
| Cost & Expenses | 45.78M | 56.84M | 54.39M | 32.81M | 24.81M |
| Interest Income | 2.34M | 781.00K | 72.00K | 91.00K | 444.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.91M | 3.27M | 3.30M | 2.93M | 2.28M |
| EBITDA | -41.13M | -42.38M | -51.35M | -31.37M | -22.82M |
| EBITDA Ratio | 0.00% | -354.71% | 0.00% | 0.00% | 0.00% |
| Operating Income | -45.78M | -44.34M | -54.39M | -32.81M | -25.11M |
| Operating Income Ratio | 0.00% | -354.71% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 2.74M | 8.34M | -257.00K | 91.00K | 744.00K |
| Income Before Tax | -43.04M | -36.00M | -54.65M | -32.72M | -24.36M |
| Income Before Tax Ratio | 0.00% | -288.03% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -8.34M | -2.14M | -91.00K | 0.00 |
| Net Income | -43.04M | -27.67M | -52.51M | -32.63M | -24.36M |
| Net Income Ratio | 0.00% | -221.35% | 0.00% | 0.00% | 0.00% |
| EPS | -21.33 | -11.95 | -22.48 | -41.01 | -61.94 |
| EPS Diluted | -21.33 | -11.95 | -22.48 | -41.01 | -61.94 |
| Weighted Avg Shares Out | 2.02M | 2.31M | 2.34M | 795.60K | 393.31K |
| Weighted Avg Shares Out (Dil) | 2.02M | 2.31M | 2.34M | 795.60K | 393.31K |
Source: https://incomestatements.info
Category: Stock Reports